Linoleic acid–rich oil versus blended oil for adults with insulin resistance

Role of Linoleic Acid in Cardiometabolic Health Beyond Its Lipid-lowering Effects, and Its Dietary and Pathophysiological Implications

Not applicable Interventional Pontificia Universidad Catolica de Chile · NCT07287514

This trial will test whether taking a linoleic acid–rich oil daily for 8 weeks improves insulin resistance in adults who already have insulin resistance.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment120 (estimated)
Ages20 Years to 60 Years
SexAll
SponsorPontificia Universidad Catolica de Chile Academic / other
Locations1 site (Santiago, Santiago Metropolitan)
Trial IDNCT07287514 on ClinicalTrials.gov

What this trial studies

In a single-blind, randomized, parallel-group intervention, adults with insulin resistance will be assigned to take either a linoleic acid–rich oil supplement or a control blended oil each day for 8 weeks while keeping their usual diet and lifestyle. The main outcome is change in insulin resistance measured by HOMA-IR, with secondary outcomes including fasting glucose and insulin, lipid profile, inflammatory and oxidative stress markers, and body composition. Participants are adults aged 20–60 with HOMA-IR > 2.6 and at least one cardiometabolic risk factor, and people with diabetes, prior cardiovascular disease, or on certain medications are excluded. The trial is conducted at a single clinical research center and aims to provide controlled randomized data on the metabolic effects of increasing dietary linoleic acid.

Who should consider this trial

Good fit: Adults aged 20–60 with documented insulin resistance (HOMA-IR > 2.6) and at least one cardiometabolic risk factor who are not diabetic and are not taking medications that affect lipids or insulin sensitivity are ideal candidates.

Not a fit: People with diagnosed diabetes, prior clinical cardiovascular disease, recent bariatric surgery, pregnancy or lactation, malabsorption disorders, or regular use of excluded medications or PUFA supplements are unlikely to benefit from participation.

Why it matters

Potential benefit: If successful, this intervention could offer a simple dietary supplement approach to improve insulin sensitivity and related metabolic markers in people with insulin resistance.

How similar studies have performed: Observational studies and meta-analyses have linked higher linoleic acid intake to better lipid profiles and lower diabetes risk, but well-controlled randomized trials testing metabolic outcomes remain limited.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Men and women aged 20 to 60 years.
* Insulin resistance (HOMA-IR \> 2.6).
* At least one cardiometabolic risk factor: abdominal obesity (waist circumference \> 90 cm in men or \> 80 cm in women); low HDL-cholesterol (\< 40 mg/dL in men or \< 50 mg/dL in women); elevated LDL-cholesterol (\> 70 / 100 / 130 mg/dL, according to estimated cardiovascular risk); or elevated blood pressure (≥ 130/85 mmHg).

Exclusion Criteria:

* Diabetes diagnosis.
* Severe psychiatric illness.
* Malabsorption disorders or previous bariatric surgery.
* Pregnancy or lactation.
* Previous clinical cardiovascular disease.
* Regular use of medications that could influence study outcomes, including:

lipid-lowering agents insulin sensitizers antihypertensive drugs anticoagulants antiretroviral therapy thyroid hormones oral corticosteroids immunosuppressants polyunsaturated fatty acid (PUFA) supplements.

* Fasting serum triglycerides ≥ 500 mg/dL or LDL-cholesterol ≥ 190 mg/dL.
* Body mass index (BMI) ≥ 35 kg/m².
* Very high blood pressure.
* Any additional condition that may limit adherence to the study.

Where this trial is running

Santiago, Santiago Metropolitan

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Insulin ResistanceMetabolic Diseaselinoleic acidomega-6 fatty acid
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.